TISIDB

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Lipid-anchor Cytoplasmic side Golgi apparatus membrane Lipid-anchor Note=Shuttles between the plasma membrane and the Golgi apparatus.
Domain	PF00071 Ras family
Function	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.

> Gene Ontology [ TOP ]
Biological Process	GO:0002218 activation of innate immune response GO:0002220 innate immune response activating cell surface receptor signaling pathway GO:0002223 stimulatory C-type lectin receptor signaling pathway GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0007173 epidermal growth factor receptor signaling pathway GO:0007265 Ras protein signal transduction GO:0007409 axonogenesis GO:0007411 axon guidance GO:0031349 positive regulation of defense response GO:0034067 protein localization to Golgi apparatus GO:0038093 Fc receptor signaling pathway GO:0038095 Fc-epsilon receptor signaling pathway GO:0038127 ERBB signaling pathway GO:0038128 ERBB2 signaling pathway GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0048667 cell morphogenesis involved in neuron differentiation GO:0050900 leukocyte migration GO:0061564 axon development GO:0072600 establishment of protein localization to Golgi GO:0097485 neuron projection guidance
Molecular Function	GO:0005525 GTP binding GO:0019001 guanyl nucleotide binding GO:0032561 guanyl ribonucleotide binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04010 MAPK signaling pathway hsa04012 ErbB signaling pathway hsa04014 Ras signaling pathway hsa04015 Rap1 signaling pathway hsa04062 Chemokine signaling pathway hsa04068 FoxO signaling pathway hsa04071 Sphingolipid signaling pathway hsa04140 Regulation of autophagy hsa04150 mTOR signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04210 Apoptosis hsa04360 Axon guidance hsa04370 VEGF signaling pathway hsa04540 Gap junction hsa04550 Signaling pathways regulating pluripotency of stem cells hsa04650 Natural killer cell mediated cytotoxicity hsa04660 T cell receptor signaling pathway hsa04662 B cell receptor signaling pathway hsa04664 Fc epsilon RI signaling pathway hsa04720 Long-term potentiation hsa04722 Neurotrophin signaling pathway hsa04725 Cholinergic synapse hsa04726 Serotonergic synapse hsa04730 Long-term depression hsa04810 Regulation of actin cytoskeleton hsa04910 Insulin signaling pathway hsa04912 GnRH signaling pathway hsa04915 Estrogen signaling pathway hsa04916 Melanogenesis hsa04917 Prolactin signaling pathway hsa04919 Thyroid hormone signaling pathway hsa04921 Oxytocin signaling pathway
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-1169092: Activation of RAS in B cells R-HSA-1280218: Adaptive Immune System R-HSA-422475: Axon guidance R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-5621575: CD209 (DC-SIGN) signaling R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-5637810: Constitutive Signaling by EGFRvIII R-HSA-1236382: Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR) R-HSA-5654687: Downstream signaling of activated FGFR1 R-HSA-5654696: Downstream signaling of activated FGFR2 R-HSA-5654708: Downstream signaling of activated FGFR3 R-HSA-5654716: Downstream signaling of activated FGFR4 R-HSA-2179392: EGFR Transactivation by Gastrin R-HSA-2871796: FCERI mediated MAPK activation R-HSA-5654693: FRS-mediated FGFR1 signaling R-HSA-5654700: FRS-mediated FGFR2 signaling R-HSA-5654706: FRS-mediated FGFR3 signaling R-HSA-5654712: FRS-mediated FGFR4 signaling R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-179812: GRB2 events in EGFR signaling R-HSA-1963640: GRB2 events in ERBB2 signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-5674135: MAP2K and MAPK activation R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-8851805: MET activates RAS signaling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-5675221: Negative regulation of MAPK pathway R-HSA-6798695: Neutrophil degranulation R-HSA-6802957: Oncogenic MAPK signaling R-HSA-8849471: PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF R-HSA-169893: Prolonged ERK activation events R-HSA-5673000: RAF activation R-HSA-5673001: RAF/MAP kinase cascade R-HSA-6802953: RAS signaling downstream of NF1 loss-of-function variants R-HSA-8853659: RET signaling R-HSA-5658442: Regulation of RAS by GAPs R-HSA-5654688: SHC-mediated cascade R-HSA-5654699: SHC-mediated cascade R-HSA-5654704: SHC-mediated cascade R-HSA-5654719: SHC-mediated cascade R-HSA-2428933: SHC-related events triggered by IGF1R R-HSA-180336: SHC1 events in EGFR signaling R-HSA-1250196: SHC1 events in ERBB2 signaling R-HSA-1250347: SHC1 events in ERBB4 signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-6802952: Signaling by BRAF and RAF fusions R-HSA-177929: Signaling by EGFR R-HSA-1643713: Signaling by EGFR in Cancer R-HSA-5637812: Signaling by EGFRvIII in Cancer R-HSA-1227986: Signaling by ERBB2 R-HSA-1236394: Signaling by ERBB4 R-HSA-190236: Signaling by FGFR R-HSA-1226099: Signaling by FGFR in disease R-HSA-5654736: Signaling by FGFR1 R-HSA-5655302: Signaling by FGFR1 in disease R-HSA-5654738: Signaling by FGFR2 R-HSA-5655253: Signaling by FGFR2 in disease R-HSA-5654741: Signaling by FGFR3 R-HSA-8853334: Signaling by FGFR3 fusions in cancer R-HSA-5655332: Signaling by FGFR3 in disease R-HSA-8853338: Signaling by FGFR3 point mutants in cancer R-HSA-5654743: Signaling by FGFR4 R-HSA-5655291: Signaling by FGFR4 in disease R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-5637815: Signaling by Ligand-Responsive EGFR Variants in Cancer R-HSA-6806834: Signaling by MET R-HSA-186797: Signaling by PDGF R-HSA-8848021: Signaling by PTK6 R-HSA-6802949: Signaling by RAS mutants R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-6802948: Signaling by high-kinase activity BRAF mutants R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants R-HSA-983705: Signaling by the B Cell Receptor (BCR) R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-210993: Tie2 Signaling R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation R-HSA-171007: p38MAPK events

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04010 MAPK signaling pathway
hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04062 Chemokine signaling pathway
hsa04068 FoxO signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04140 Regulation of autophagy
hsa04150 mTOR signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04210 Apoptosis
hsa04360 Axon guidance
hsa04370 VEGF signaling pathway
hsa04540 Gap junction
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
hsa04720 Long-term potentiation
hsa04722 Neurotrophin signaling pathway
hsa04725 Cholinergic synapse
hsa04726 Serotonergic synapse
hsa04730 Long-term depression
hsa04810 Regulation of actin cytoskeleton
hsa04910 Insulin signaling pathway
hsa04912 GnRH signaling pathway
hsa04915 Estrogen signaling pathway
hsa04916 Melanogenesis
hsa04917 Prolactin signaling pathway
hsa04919 Thyroid hormone signaling pathway
hsa04921 Oxytocin signaling pathway

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-1169092: Activation of RAS in B cells
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5621575: CD209 (DC-SIGN) signaling
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-5637810: Constitutive Signaling by EGFRvIII
R-HSA-1236382: Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-5654687: Downstream signaling of activated FGFR1
R-HSA-5654696: Downstream signaling of activated FGFR2
R-HSA-5654708: Downstream signaling of activated FGFR3
R-HSA-5654716: Downstream signaling of activated FGFR4
R-HSA-2179392: EGFR Transactivation by Gastrin
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-5654693: FRS-mediated FGFR1 signaling
R-HSA-5654700: FRS-mediated FGFR2 signaling
R-HSA-5654706: FRS-mediated FGFR3 signaling
R-HSA-5654712: FRS-mediated FGFR4 signaling
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-1963640: GRB2 events in ERBB2 signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5674135: MAP2K and MAPK activation
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-8851805: MET activates RAS signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5675221: Negative regulation of MAPK pathway
R-HSA-6798695: Neutrophil degranulation
R-HSA-6802957: Oncogenic MAPK signaling
R-HSA-8849471: PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673000: RAF activation
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-6802953: RAS signaling downstream of NF1 loss-of-function variants
R-HSA-8853659: RET signaling
R-HSA-5658442: Regulation of RAS by GAPs
R-HSA-5654688: SHC-mediated cascade
R-HSA-5654699: SHC-mediated cascade
R-HSA-5654704: SHC-mediated cascade
R-HSA-5654719: SHC-mediated cascade
R-HSA-2428933: SHC-related events triggered by IGF1R
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-1250196: SHC1 events in ERBB2 signaling
R-HSA-1250347: SHC1 events in ERBB4 signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-6802952: Signaling by BRAF and RAF fusions
R-HSA-177929: Signaling by EGFR
R-HSA-1643713: Signaling by EGFR in Cancer
R-HSA-5637812: Signaling by EGFRvIII in Cancer
R-HSA-1227986: Signaling by ERBB2
R-HSA-1236394: Signaling by ERBB4
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654736: Signaling by FGFR1
R-HSA-5655302: Signaling by FGFR1 in disease
R-HSA-5654738: Signaling by FGFR2
R-HSA-5655253: Signaling by FGFR2 in disease
R-HSA-5654741: Signaling by FGFR3
R-HSA-8853334: Signaling by FGFR3 fusions in cancer
R-HSA-5655332: Signaling by FGFR3 in disease
R-HSA-8853338: Signaling by FGFR3 point mutants in cancer
R-HSA-5654743: Signaling by FGFR4
R-HSA-5655291: Signaling by FGFR4 in disease
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-5637815: Signaling by Ligand-Responsive EGFR Variants in Cancer
R-HSA-6806834: Signaling by MET
R-HSA-186797: Signaling by PDGF
R-HSA-8848021: Signaling by PTK6
R-HSA-6802949: Signaling by RAS mutants
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-6802948: Signaling by high-kinase activity BRAF mutants
R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-210993: Tie2 Signaling
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-171007: p38MAPK events

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NRAS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between NRAS and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26343581	Melanoma	Inhibit immunity	Genetic ablation of cyclooxygenases (COX) or prostaglandin E synthases in Braf(V600E) mouse melanoma cells, as well as in Nras(G12D) melanoma or in breast or colorectal cancer cells, renders them susceptible to immune control and provokes a shift in the tumor inflammatory profile toward classic anti-cancer immune pathways.
18008004	Melanoma	Inhibit immunity (T cell function)	Employing 2 independent, genome-wide microarray analyses, we identified CD200 as a highly dynamic, downstream target of RAS/RAF/MEK/ERK activation in melanoma. CD200 protein was similarly overexpressed in human melanoma cell lines and primary tumors. Melanoma cell lines expressing endogenous CD200 repressed primary T cell activation by DCs, while knockdown of CD200 by shRNA abrogated this immunosuppressive effect.

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NRAS in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NRAS in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.035	0.881
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.186	0.931
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.189	0.897
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.077	0.867
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.543	0.65
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.861	0.565
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.131	0.766
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.386	0.843
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.166	0.939
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.032	0.98
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.316	0.876
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.106	0.136

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NRAS in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	22.2	23.3	-1.1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	22.2	28.8	-6.6	0.607
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	28.6	17.6	11	0.476
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	30.8	27.3	3.5	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	26.3	14.8	11.5	0.363
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	18.2	7.7	10.5	0.63
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	37.5	21.4	16.1	0.44
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NRAS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NRAS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NRAS. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NRAS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NRAS expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NRAS and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NRAS
Name	neuroblastoma RAS viral (v-ras) oncogene homolog
Aliases	N-ras; ALPS4; CMNS; NCMS1; NS6; N-ras protein part 4; transforming protein N-Ras; v-ras neuroblastoma RAS vi ......
Chromosomal Location	1p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NRAS collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NRAS